Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM

[1]  M. Weichenthal,et al.  Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Schadendorf,et al.  Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. , 2022, The New England journal of medicine.

[3]  J. Pearson,et al.  Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. , 2021, Cancer cell.

[4]  M. Weichenthal,et al.  Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma , 2021, Frontiers in Oncology.

[5]  M. Weichenthal,et al.  Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study. , 2021 .

[6]  Jun Xu,et al.  Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy , 2021, Medicine.

[7]  J. Larkin,et al.  Immunotherapy use outside clinical trial populations: never say never? , 2021, Annals of Oncology.

[8]  C. Garbe,et al.  Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors , 2021, Targeted Oncology.

[9]  Y. Kong,et al.  Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A multidimensional analysis , 2020, EBioMedicine.

[10]  Z. Lengyel,et al.  Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in patients with melanoma , 2020, Journal for immunotherapy of cancer.

[11]  J. Roth,et al.  Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  A. Regev,et al.  Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma , 2019, Nature Medicine.

[13]  G. Hortobagyi,et al.  Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. , 2019, Cancer cell.

[14]  David L Rimm,et al.  Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. , 2019, JAMA oncology.

[15]  Dirk Schadendorf,et al.  Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[16]  Carola Berking,et al.  Melanoma , 2018, The Lancet.

[17]  J. Gershenwald,et al.  The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care , 2018, Expert review of anticancer therapy.

[18]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[19]  Wiktor Paskal,et al.  Intratumor and Intertumor Heterogeneity in Melanoma , 2017, Translational oncology.

[20]  M. Atkins,et al.  Predictive biomarkers for checkpoint inhibitor-based immunotherapy. , 2016, The Lancet. Oncology.

[21]  C. Slingluff,et al.  PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome , 2016, Oncoimmunology.

[22]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[23]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[24]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[25]  J. Madore,et al.  PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials , 2015, Pigment cell & melanoma research.

[26]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[27]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[28]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[29]  S. Steinberg,et al.  Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration , 2014, Clinical Cancer Research.

[30]  C. Slingluff,et al.  Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. , 2012, Cancer research.

[31]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[32]  C. Marquette,et al.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.